Bioventus (NASDAQ:BVS) Issues Earnings Results

Bioventus (NASDAQ:BVS) released its quarterly earnings results on Wednesday. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22, FiscalAI reports. The company had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 29.77% and a net margin of 9.36%. Bioventus updated its FY 2026 guidance to 0.750-0.790 EPS.

Here are the key takeaways from Bioventus’ conference call:

• Positive Sentiment: Bioventus reported second-quarter revenue of $153 million, up 4% year over year, with Pain Treatments revenue rising 12% to $82 million, led by double-digit volume growth in DUROLANE.
• Positive Sentiment: The company reaffirmed its 2026 guidance for revenue of $600 million–$610 million, adjusted EPS of $0.75–$0.79, and operating cash flow of $84 million–$89 million, while expecting stronger growth in the second half.
• Positive Sentiment: Management cited encouraging adoption indicators for PRP, PNS, and Ultrasonics, including accelerating capital placements, disposable reorders, trial-to-implant conversions, and new large-account wins. It plans to increase investment in these growth drivers, particularly PNS, in the second half.
• Positive Sentiment: Adjusted EBITDA margin expanded to 23%, adjusted EPS increased to $0.22, and the company repaid $24 million of debt during the quarter. Net leverage fell below 2x, with management targeting below 1.5x by year-end.
• Neutral Sentiment: The board launched a strategic review after receiving multiple expressions of interest and an unsolicited acquisition proposal, with options including a potential sale or continued standalone execution. Management provided no further details on timing or valuation.

Bioventus Stock Down 0.6%

Shares of BVS traded down $0.09 during mid-day trading on Friday, reaching $13.89. The company’s stock had a trading volume of 292,782 shares, compared to its average volume of 528,212. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 1.94 and a beta of 0.63. The business has a fifty day moving average of $10.70 and a 200 day moving average of $9.66. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. Bioventus has a 1 year low of $6.26 and a 1 year high of $15.89.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Craig Hallum reiterated a “buy” rating and issued a $18.00 target price on shares of Bioventus in a report on Thursday. Barrington Research set a $18.00 target price on shares of Bioventus in a report on Thursday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Bioventus in a report on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Bioventus currently has a consensus rating of “Buy” and a consensus price target of $16.25.

Institutional Investors Weigh In On Bioventus

Several hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd grew its stake in Bioventus by 17,156.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Bioventus during the fourth quarter worth approximately $80,000. Diversified Trust Co purchased a new position in Bioventus during the first quarter valued at approximately $100,000. Prelude Capital Management LLC purchased a new position in Bioventus during the third quarter valued at approximately $74,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Bioventus in the 3rd quarter valued at approximately $78,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.